



26

27 **Abstract**

28 Human brucellosis in Ecuador is underreported and based only on passive surveillance.  
29 Since 2008, brucellosis was removed from the list of communicable diseases in the  
30 country. Until now, the true human brucellosis picture has not yet been determined. The  
31 aim of this study was to determine the seroprevalence of the disease, to identify risk  
32 factors associated with brucellosis seropositivity in humans and to isolate circulating  
33 strains of *Brucella* spp. in the north-western part of Ecuador.

34 Between 2006 and 2008, a large transect survey was conducted, based on blood  
35 sampling of people from the north-western part of Ecuador (N=3,733) together with an  
36 epidemiological inquiry. Based on three diagnostic tests used in parallel, the overall  
37 seroprevalence was estimated as 1.88% (95% C.I.: 1.48-2.38). Based on a multivariable  
38 random effects logistic regression analysis, the main risk factors associated with human  
39 brucellosis seropositivity were: contact with livestock (OR = 3.0; C.I.: 1.25 – 7.08),  
40 consumption of foetus and placenta (OR = 2.5; C.I.: 1.18 – 5.22) and involvement in  
41 activities at risk for brucellosis infection (OR =1.8; C.I.: 1.00 – 3.35). Noticeable  
42 variation in brucellosis seropositivity among humans within cantons was observed. The  
43 circulating strain was *Brucella abortus* biotype 4.

44 The study emphasized that contact with livestock, consumption of foetus and placenta  
45 and occupational hazard group were all significant risk factors for the transmission of  
46 brucellosis among individuals in the north-western part of Ecuador. Alongside  
47 encouraging the launching of educational campaigns against brucellosis, especially in  
48 rural areas where 36% of the population lives, controlling this zoonotic disease in  
49 animals will directly benefit its prevention in humans especially since there is no safe  
50 and efficacious vaccine against brucellosis in humans.

51

52 **Keywords:** Brucellosis; Human; Ecuador; Serological tests; True prevalence; Risk  
53 factors; *Brucella abortus* biotype 4

54

## 55 **Introduction**

56 Brucellosis is an infectious and contagious disease caused by Gram-negative  
57 coccobacilli, which can survive in the cells of the immune system. It has a high  
58 tendency to cause chronic infections both in humans and in cattle (Young 2007,  
59 Moriyon 2001, Torres et al. 2004, Saegerman 2010).

60 In many countries, brucellosis is an important disease that causes serious economic  
61 losses in cattle production (FAO 2003, Guillén 2006, WHO 2006). In Ecuador these  
62 losses are estimated at 5.5 million US\$ per year (Torres 2008). In humans, this zoonosis  
63 mainly leads to losses in working time and costs related to diagnosis and treatment  
64 (Bowden 1996).

65 In Latin America, four in ten people live in areas where brucellosis is endemic in natural  
66 animal reservoirs (Alvarez 2001). However, the infection in humans is underestimated  
67 and often not reported (Dean et al., 2012) and only few reports exist concerning the  
68 identification of circulating strains of *Brucella* spp. (e.g. Deodato et al., 2011 ; Aznar et  
69 al., 2012; Ron-Román et al., 2012). In addition, the true incidence of this zoonosis has  
70 not yet been estimated (Lucero et al 2008; Aznar et al., 2012).

71 In Ecuador, by means of diagnostic assays with low sensitivity, several authors have  
72 reported the presence of antibodies against *Brucella* spp. mainly among slaughterhouse  
73 workers: Intriago (1971) reported a prevalence of 4% (1/25), León (1979 cited by  
74 Delgado 1992) detected 10.90% (23/211), Zurita (1980, cited by Díaz 2001) detected

75 23.83% (56/235) and finally Delgado (1992) mentioned a seroprevalence of 2.32%  
76 (4/173).

77 Despite brucellosis being a communicable disease in Ecuador since 2007, the true  
78 incidence of human cases remains largely unknown. According to the Ministry of  
79 Health (MSP), only 111 human cases were reported between 1990 and 2007 (EPI-2  
80 2008), whereas, the National Institute for Statistics and Census (INEC) registered 152  
81 persons hospitalised for brucellosis between 1995 and 2007 (INEC 2008).

82 The aim of the present work was to obtain a realistic figure of the prevalence of human  
83 brucellosis by determining the seroprevalence of antibodies against *Brucella* spp., and  
84 by identifying the causal agent together with possible infection-associated risk factors  
85 among people living and/or working in the north-western part of Ecuador.

86

## 87 **Materials and methods**

### 88 *Description of the study and selection of the study region*

89 Between 2006 and 2008, a transect study was conducted, based on blood sampling of  
90 people from the north-western part of Ecuador together with an epidemiological survey.

91 After informed consents were obtained, blood samples were taken from persons  
92 inhabiting the high-altitude or Sierra provinces such as Carchi, eastern Imbabura,  
93 eastern Pichincha and the coastal provinces such as Esmeraldas, Manabí, western  
94 Imbabura and western Pichincha.

95 Selection of provinces was based on the high provincial-level seroprevalence of bovine  
96 brucellosis reported in Ecuador. Seroprevalence was officially estimated to be between  
97 4.0% and 10.62% in the Sierra and between 5.88% and 10.62% in the Coast (Torres  
98 2008, MAG-SESA 1999). Prior to this study, the seroprevalence was also estimated to  
99 be between 2.17% and 9.42% using the Rose Bengal Test (RB) and indirect Enzyme

100 Linked Immunosorbent Assay (iELISA), respectively in bovines of Santo Domingo  
101 (Pichincha) and between 1.08 and 9.73% to RB and iELISA, respectively in El Carmen  
102 (Manabí) (Angula and Tufino, 2005). The selection of the study zone was also based on  
103 the occurrence of 41.30% (19/46) of the human cases, as reported by MSP between  
104 1997 and 2007 (EPI-2 2008) and 51.97% (79/152) of the hospitalized brucellosis  
105 patients, as reported by INEC (2008). In addition, since sheep, goats and camel  
106 populations are very small in the study area, only the link between brucellosis  
107 seroprevalence in bovines and humans was investigated. A map of the study area is  
108 shown on Figure 1.

109

### 110 *Samples*

111 After informed consent, a total of 3,733 blood samples were taken from people with  
112 different occupational hazards. A first possible high-risk group of people (n=2,444)  
113 consisted of labourers at cattle farms, slaughterhouse workers, meat and organ traders,  
114 cattle traders, veterinarians, zoo workers, teachers and students from a faculty of animal  
115 production and farm and slaughterhouse managers. A second possible low-risk group of  
116 people (n=1,289) consisted of agricultural labourers, informal traders, public servants,  
117 school and college teachers and students, house workers and transporters.

118 Alongside collecting blood samples, other information was collected through personal  
119 face-to-face interviews. The questionnaire recorded the following information for each  
120 subject: age, sex, consumption of raw milk (yes or no), consumption of blood (yes or  
121 no), consumption of cheese (yes or no), region (Sierra or tropical), consumption of  
122 foetus or placenta (yes or no), occupational hazard group, contact with animals (yes or

123 no) and presence of symptoms such as pyrexia, weakness, sweating, muscle pain,  
124 backache, and headache suggestive of brucellosis (Mantur et al. 2006).

125 Based on results of the questionnaire the people were divided into two groups, *i.e.* those  
126 working directly or indirectly in a slaughterhouse (n=542) and those who were not  
127 (n=3,191). The full questionnaire is available upon request from the corresponding  
128 author.

129

### 130 ***Diagnostic assays***

131 Three serological assays to detect antibodies against *Brucella* spp. were used: Rose  
132 Bengal fast agglutination test (RBT), Wright's Slow Agglutination Test with EDTA  
133 (SAT-EDTA) and indirect Enzyme Linked Immunosorbent Assay (iELISA). Samples  
134 were processed and analysed in the laboratory for immunodiagnosis at the International  
135 Centre for Zoonoses (CIZ) of the Central University of Ecuador (UCE).

136

### 137 **Rose Bengal fast agglutination test (RB)**

138 The RB assay was used with Bengatest<sup>®</sup> antigen *i.e.* a concentrated suspension (4% v/v)  
139 of *B. abortus* Weybridge strain 19, heat and phenol (0.5%) inactivated, suspended in an  
140 acid buffer and stained with Rose Bengal. Equal quantities (30 µl) of serum and antigen  
141 were mixed in a well (4 min) on a glass plate and any degree of agglutination was  
142 considered a positive reaction.

143

### 144 **Wright's Slow Agglutination Test with EDTA (SAT-EDTA)**

145 For SAT-EDTA, the antigen (Antigen SAW<sup>®</sup>, Synbiotics code # ASAW) was a  
146 concentrated suspension of *B. abortus* (strain 1119/3), heat and phenol (0.5%)  
147 inactivated and suspended in a phenol-buffer at 0.5%. The assay was performed as

148 described by Godfroid & Boelaert, (1995) with serum dilutions of 1/12.5, 1/25, 1/50,  
149 1/100, 1/200, 1/400, 1/800, 1/1,600, 1/3,200, 1/6,400, 1/12,800 and 1/25,600 in a  
150 constant volume (100 µl) of antigen. Quantitative results were given as International  
151 Units of Agglutination (IU/ml). A value equal to or above 100 IU/ml, corresponding to  
152 75% transparency of dilution 1/50), was considered as a positive reaction.

153

#### 154 **Indirect Enzyme Linked Immunosorbent Assay (iELISA)**

155 The assay was performed according to Godfroid & Boelaert (1995). Smooth *B. abortus*  
156 Weybridge strain 19 lipopolysaccharide (LPS) antigen was incubated on polystyrene  
157 plates for 3.5 h at 37°C and overnight at 4°C. Plates were washed 5 times with a  
158 washing solution (NaCl 0.9% + Tween 20 at 0.01%).

159 Then, 50 µl of 1/50 diluted serum in glycine-EDTA-Tween 80 buffer (BB) was added  
160 per well and the calibration curve was determined at dilutions 1/270, 1/540, 1/1,080,  
161 1/2,160, 1/4,320, 1/8,640. After one hour incubation at ambient temperature, the  
162 solutions were discarded, plates were washed 5 times and 50 µl conjugate (Protein G-  
163 HRPO, Pirce CD47675, diluted at 1/1,500 in G - HRPO + FCS at 2%) was added to  
164 each well and left to incubate at ambient temperature for 1 hour.

165 The same washing procedure was repeated and 100 µl substrate solution (i.e. *o*-PD  
166 Ortho-phenyldiamine tablets, SIGMA P-8287, one tablet of 10 mg dissolved in 25 ml  
167 citrate phosphate buffer SIGMA P-4809 + 5 µl H<sub>2</sub>O<sub>2</sub> at 30%) was added to each well.  
168 Plates were left to incubate for 20 min in the dark at ambient temperature. Subsequently  
169 the reaction was stopped by adding 25 µl H<sub>2</sub>SO<sub>4</sub> (2M) to each well. Optical densities  
170 (OD) were read by a spectrophotometer (STAT FX 2100), with filters between 492nm  
171 and 630nm. Mean OD values of the samples and the calibration curve were corrected by  
172 subtracting the mean BB from the mean OD.

173 A cut off value, above which a sample was considered positive was set at or above 20  
174 units (U)/ml. This cut-off value was established based on local epidemiological  
175 conditions and to optimize the compromise between sensitivity and specificity (Franco  
176 et al., 2007; Gómez et al., 2008; Soudbakhsh et al., 2009).

177 Calculation of the units was based on the reference values of the curve i.e. 1.87 U, 3.75  
178 U, 7.5 U, 15 U, 30 U, and 60 U, for dilutions 1/270, 1/540, 1/1,080, 1/2,160, 1/4,320,  
179 1/8,640 respectively.

180

181 ***Isolation and typing of Brucella spp.*** (according to Alton et al. (1988))

182 Due to the lack of standardized procedures in Ecuador, the isolation of the causal agent  
183 was based on blood cultures - BACTEC (3 repetitions with 30 minutes-intervals) from  
184 persons with high serotitres (n=22) (Yagupsky, 1994; Cetin et al., 2007). Blood cultures  
185 were done at the “Hospital Vozandes Quito”, where they were maintained for 30 days,  
186 and after those days the cultures were considered as negatives.

187 Isolated *Brucella* were identified and typified by CIZ and also by Veterinary and  
188 Agrochemical Research Centre (VAR-CERVA) as a reference laboratory using (1)  
189 macroscopic and microscopic observation of the colonies in cultures, (2) biochemical  
190 assays (oxydase, catalase and urease), (3) production of H<sub>2</sub>S, (4) CO<sub>2</sub> growth  
191 requirement, (5) growth in stained media (thionine, basic fuchsin, safranin), (6)  
192 agglutination with mono-specific sera A and M, and (7) PCR – AMOS as described by  
193 Bricker and Halling (1994).

194

195 ***Statistical analysis***

196 To determine the potential risk factors associated with human brucellosis sero-  
197 positivity, a two stage modelling approach was used. In this approach, individuals were



198 considered positive if they tested positive in at least one serological test along with the  
199 presence of any of the clinical symptoms suggestive of brucellosis as previously  
200 mentioned.

201 Firstly, a univariate analysis was performed using a random effects logistic regression  
202 model. The model used as response, the brucellosis status of the individuals (1 for  
203 positive and 0 for negative) and each risk factor or indicator variable in turn as the  
204 independent variable. The possible effects of variations in brucellosis seropositivity  
205 among the different provinces and cantons were accounted for by incorporating  
206 province and canton as a random effects in the model (VanLeeuwen et al. 2010).

207 Secondly, variables with a p-value  $\leq 0.25$  in the univariate analysis were further  
208 analysed in a multivariable random effects logistic regression model. A manual forward  
209 stepwise model building approach was employed with the Akaike's Information  
210 Criterion (AIC) as the calibrating parameter to select the final model. The model with  
211 the smallest AIC is considered to be the most appropriate model. All two-way  
212 interaction terms of the variables remaining in the final model were assessed for  
213 significance. The effects of confounding were investigated by observing the change in  
214 the estimated coefficients of the variables that remain in the final model once a non-  
215 significance variable is included. When the inclusion of a non-significant variable led to  
216 a change of more than 25% of any parameter estimate, that variable was considered to  
217 be a confounder and was included in the model (Dohoo et al. 2003).

218 The intra-class correlation coefficient (ICC), which is a measure of the degree of  
219 clustering of individuals belonging to the same province and canton, was computed  
220 (Snijders and Bosker 1999).

221 The models were built using the `xtmelogit ()` function in STATA, version 12, software  
222 (SataCorp LP, College station, Texas). Model selection was done using Laplacian

223 approximation whereas parameter estimates from the final model were obtained using  
224 Adaptive Gaussian Quadrature (Twisck 2003). The robustness of the final model was  
225 assessed by increasing the number of Quadrature (integration) points and monitoring  
226 changes in parameter estimates (Frankena et al. 2009).

227

### 228 *Ethical considerations*

229 The protocol was thoroughly reviewed and approved for ethics by the Bioethics  
230 Committee of the Biomedical Center, Central University of Ecuador. Prior to being  
231 included in the study, all participants provided informed written consent. For minors,  
232 parents/guardians provided consent on their behalf.

233

### 234 **Results**

#### 235 *Descriptive statistics*

236 A total of 3,733 persons, with a mean age of  $30.03 \pm 16.26$  years (min=3, max=89  
237 years) were sampled in five provinces in the north-western part of Ecuador: Carchi,  
238 Imbabura, Esmeraldas, Manabí and Pichincha. Seventy people with mean age  $37.86 \pm$   
239  $14.81$  years (min=10, max=79 years) reacted positive to at least one of the three  
240 diagnostic tests, representing an overall sero-prevalence of 1.88% (C.I. 1.48 -2.38). The  
241 proportion of seropositive people between groups (slaughterhouse workers *versus* other  
242 people) was 4.8% (26/542) and 1.4% (44/3,191), respectively. This suggests a  
243 preferential repartition of seropositive people in slaughterhouse workers (Pearson' chi-  
244 squared test = 29.4;  $P < 0.001$ ).

245 The distribution of the number of individuals tested, the number and percentage of  
246 seropositives is presented in Table I. Besides teenagers and children represented 20.84%  
247 (778/3,733) of the sample with only six of them being seropositive (3 originating from

248 farms). The information about this sub-population is presented in the Table II. This  
249 suggests a preferential repartition of seropositive cases among older people (Pearson'  
250 chi-squared test = 6.50;  $P=0.01$ ).

251

252 *Risk factors for human brucellosis seropositivity based on the univariate random*  
253 *effects logistic regression analysis*

254 Based the results of the univariate random effects logistic regression analysis with  
255 random intercepts for both province and canton, the factors; age, sex, contact with  
256 livestock, contact with foetal secretions, consumption of foetus and placenta and  
257 involvement in activities at risk were all statistically significantly associated with  
258 human brucellosis seropositivity ( $p < 0.05$ ) (Table III). On the other hand consumption  
259 of raw cow milk and consumption of fresh blood were not significant at the 5% level  
260 but since their p-values were  $\leq 0.25$ , they were considered as potential risk factors and  
261 were thus included in the multivariate random effects logistic regression analysis.

262

263 *Final model based on multivariate random effects logistic regression analysis*

264 Out of the potential risk factors initially considered in the multivariate random effects  
265 logistic regression model, 3 were included in the final model (*i.e.*, **consumption of**  
266 **foetus and placenta, contact with livestock and** occupational hazard group).

267 In addition, the results were not confounded by any of the variables not included in the  
268 final model. Increasing the number of quadrature points had no influence on the  
269 estimated fixed effects and the variance component parameters indicating that the model  
270 is robust. The estimated odds ratios and their 95% confidence intervals are presented in  
271 Table IV. There was no variability in brucellosis seropositivity among provinces but  
272 rather a higher variability among people within provinces.

273

#### 274 ***Typifying of circulating Brucella spp. in North-West Ecuador***

275 Detailed information about persons with positive blood cultures (n=22) is given in  
276 Table V with the characteristics of the isolates, bacteriological data and PCR in Table  
277 VI and Figure 2, respectively. From three positive cases, *Brucella abortus* biotype 4  
278 was isolated and typified. Blood cultures were only positive for patients with higher  
279 levels of IgM antibodies (SAT-EDTA) suggesting an acute brucellosis.

280 Retrospectively, seropositive persons (N = 70) were queried about possible symptoms  
281 related to brucellosis, a summary of the outcome based on the questionnaire is presented  
282 in Table VII.

283

#### 284 **Discussion**

285 The current study aimed to provide a reliable estimation of the sero-prevalence based on  
286 the detection of antibodies against *Brucella* spp., the isolation and the identification of  
287 the circulating strain of *Brucella* spp. and the identification of possible risk factors  
288 related to the transmission and spread of brucellosis among people in the north-western  
289 part of Ecuador.

290

#### 291 ***Prevalence of human brucellosis in the north-western part of Ecuador***

292 In the current study an overall sero-prevalence of 1.88% (C.I. 1.48 - 2.38) was found,  
293 which may be in sharp contrast with the official data of the Ecuadorian Ministry of  
294 Health MSP i.e. only 67 cases between 2003 and 2007 (EPI-2 2008). The results of the  
295 present investigation, and additional observations described by Ron-Román et al. (2012)  
296 in humans, as well as, a seroprevalence of 2% in bovines from the same study area, and  
297 numerous isolations of *Brucella* sp. from different animal reservoirs (bovines and

298 canine) (unpublished data), suggest an underreporting of human brucellosis in Ecuador  
299 considering that 36% of the population lives in rural areas (Organización Panamericana  
300 de la Salud, 2008).

301  
302 Based solely on clinical symptoms, a correct diagnosis of brucellosis is not possible  
303 (Abdoel & Smits 2006; Saegerman et al. 2010) and even microbiological blood cultures  
304 are sometimes unreliable because sensitivity is too variable and too dependent on the  
305 stage of infection (*i.e.* acute stage) and the *Brucella* species concerned (Casao et al.,  
306 2004). The difficulties related to the diagnosis and the often ambiguous or even absent  
307 clinical symptoms, also noted in the present study, are probably the principal reasons for  
308 the sub-notification (Serra and Godoy 2000, Agasthya et al. 2007).

309 The non-existence of a vaccine against brucellosis in humans or the difficulty to access  
310 a safe and efficacious vaccine implies that controlling this zoonotic disease in animals  
311 will directly benefit its prevention in humans especially to improve the biosecurity. A  
312 joint work between the Ecuadorian Ministries of Public Health (MSP) and the  
313 Livestock, Aquaculture and Fisheries (MAGAP) is needed to consolidate a “One  
314 Health” initiative.

315

### 316 ***Risk factors for human brucellosis in the north-western part of Ecuador***

317 The occupations that expose people to the infection are male dominated in this study  
318 region thus the apparent increased risk for infection. Several other studies have  
319 indicated gender as a significant risk factor for brucellosis (Wassif et al. 1992, Shehata  
320 et al. 2001, Mantur et al. 2007, Meky et al. 2007). The apparent elevated risk associated  
321 with older age groups could be explained simply by the fact that older people had more  
322 occasions to contract the disease (Cooper 1992, Kalaajieh 2000). Nevertheless, it is  
323 important to mention that 3 cases were also found in children below 15 years old,

324 confirming the findings of Guevara et al. (Guevara 2009) that children are indeed at risk  
325 and also do get the infection, e.g. due to direct or indirect contact with animals when  
326 accompanying adults handling livestock (Minas et al. 2007) or through consumption of  
327 non-pasteurised dairy products (Issa and Jamal 1999).

328 Brucellosis is mainly an occupational disease and the multivariate analysis indicated  
329 that the odds of brucellosis seropositivity among those working in slaughterhouses were  
330 higher than those of people in the general population. This is in line with the results of  
331 other studies (Omer et al. 2002, Rahman et al. 2012). The higher sero-prevalence among  
332 slaughterhouse workers confirms the proposition that intimate contact with animals is  
333 more important than consumption of infected dairy products (McDevitt 1971).

334 According to WHO (2006), temperatures for pasteurisation or boiling milk should be  
335 sufficiently high to eliminate bacteria and to render it fit for consumption. Nevertheless  
336 the relation between transmission of brucellosis and raw milk consumption in the  
337 present study was not statistically significant which is in line with Serra and Godoy  
338 (2000) reporting no link between presence of antibodies against *Brucella* spp and the  
339 unhygienic consumption of milk. This lack of an association between consumption of  
340 milk or dairy products and infection may also be due to the low number of seropositives  
341 people found in our study that consumed these products.

342 The non-significance of the consumption of cheese squares with findings from Barroso-  
343 García et al. (2007) where it was observed that the consumption of cheese is not  
344 necessarily a source of infection of brucellosis, because processing takes a few days or  
345 even weeks, affecting the number of bacteria, which was also indicated in this study.  
346 However, this information depends largely on the maturation process of each cheese  
347 considered and thus caution is recommended.

348 In general, the shedding of *B. abortus* in cows naturally infected is lower ( $< 10^3$  CFU/ml  
349 for several weeks but with decreasing after the partum) than for *B. melitensis* in small  
350 ruminants (in general  $> 10^3$  CFU/ml during all the lactating period) (Carpenter and Boak  
351 1928, Jouve 1952, Grilló et al. 1997, Hamdy and Amin 2002, Saegerman et al. 2010). In  
352 addition the human pathogenicity of *B. abortus* appears lower than *B. melitensis*  
353 (Godfroid et al. 2010). These elements are other possible explanations for the lack of  
354 evidence found in this study considering the link between consumption of milk and  
355 dairy products and brucellosis infection.

356 Traditionally, milk and dairy consumption without any sanitary measures has been  
357 considered the most important route of transmission. However, recent reports stress the  
358 prominent role of transmission by direct contact with animal reservoirs (Saegerman et  
359 al. 2010, Barroso-Garcia et al. 2007, Godfroid et al. 2010).

360 In Ecuador, a national program exists. The main objective is to obtain free brucellosis  
361 farms on a voluntary basis. In fact, this program is restricted to some farmers which are  
362 able to pay for the vaccination of calves with the B19 or RB51 vaccine, to test animals  
363 every six months and to eliminate infected animals without compensation (most often at  
364 the slaughterhouse). In addition, no control of animal movements is performed and  
365 control of dairy farms by MRT is not systematized and suffers from the lack of  
366 availability of antigen. However the milk marketed in the cities by companies is usually  
367 pasteurized. However, raw milk is sold frequently in rural and peri-urban areas.

368 This study has not demonstrated the importance of raw milk consumption in the human  
369 brucellosis transmission, in Ecuadorian conditions. However serial isolation of *B.*  
370 *abortus* (N ~ 100) from bovine raw milk of the same area (Ron-Román et al.,  
371 unpublished data) indicates that the risk exists and needs future additional investigation.

372 Not surprisingly, the consumption of foetus or placentas was significantly associated  
373 with brucellosis seropositivity. This alimentary tradition, though largely obsolete, is still  
374 commonly used by rural families, and even in public restaurants that offer Ecuadorian  
375 typical dishes called foetus (locally known as “ville”) or placentas (locally called  
376 “guagua mama - huagra mama”). This meat is cooked but handling of this food item  
377 increases risk of exposure to *Brucella* spp.

378 Unfortunately, the consumption of blood was not significantly associated with  
379 brucellosis seropositivity in Ecuadorian context. However, this practice can be at risk  
380 but necessitates a donor in the acute phase of brucellosis which is not frequent (Thiange  
381 et al. 1992).

382 Education and health campaigns should target the elimination of such practices. It has  
383 indeed been observed in the population of the north-western part of Ecuador that risks  
384 related to eating habits are mostly due to a lack of basic knowledge about brucellosis  
385 and the modes of transmission.

386

### 387 ***Typifying of circulating Brucella spp. in North-West Ecuador***

388 Biotyping *Brucella* is important for the epidemiological knowledge, since it can reveal  
389 geographical characteristics (FAO and OMS 1986) and allows a better understanding of  
390 the spread of the disease (Roux 1979). Unfortunately isolating and typing of *Brucella*  
391 spp. is not always possible since it requires high biosecurity laboratories and trained  
392 personnel. Furthermore, the low number of successful isolations in the present study is  
393 mainly due to the low number of patients with acute brucellosis (*i.e.*, with high levels of  
394 IgM antibodies) and also partly due to the localisation of the bacteria in specific tissues  
395 and organs like bone marrow, cerebrospinal fluid (CSF), liver, kidneys and spleen,  
396 which renders isolation from blood very unlikely (Doganay and Aygen 2003).



397 In the present study 24.29% of the persons with a positive sero-reaction showed no  
398 apparent symptoms at all. This is lower than the 45.6% reported by Pila-Perez et al.  
399 (Pila-Perez 1997) and the 99% found in a retrospective study of the symptomatology by  
400 Hernández et al. (1999).

401 Although according to Pappas et al. (Pappas et al. 2006), based only on few reported  
402 data, Ecuador was not considered an endemic country for human brucellosis, the present  
403 results, based on factual data, contradicted this statement, especially in rural areas where  
404 36% of the population lives. A recent report presented a systematic review of the  
405 scientific literature published between 1990 and 2010 relating to the frequency of  
406 human brucellosis in the world indicated that underestimation of the disease could be  
407 related to barriers in accessing health care or to case mismanagement and misdiagnosis  
408 (Dean et al. 2012). In Latin America, according to the previous report, reliable  
409 information was found only for Argentina and Mexico at sub-national level.

410

#### 411 **Conclusions**

412 The absence of a National Policy and differential diagnostic tests hinders the  
413 development of surveillance and control programmes in high-risk areas for human  
414 brucellosis (especially in rural areas). It is thus difficult to have a realistic idea about the  
415 incidence of this disease. In the past, little attention was given to brucellosis in Ecuador  
416 and it is necessary to develop programmes to control (and eventually eradicate)  
417 brucellosis in the identified risk areas whereby highly sensitive diagnostic methods  
418 should be used both for humans and for animals with the objective to obtain an early  
419 warning system and to determine the correct prevalence at national level.

420 In view of the results of this study, there is an urgent need for information campaigns,  
421 especially in rural area, about the risks involved following direct contact with livestock

422 and consumption of foetus and placenta and equally about the preventive care as to  
423 avoid infection. Also, more investigations to isolate and identify the biotypes of  
424 *Brucella* spp. circulating in Ecuador should be followed.

425 Finally, it is of utmost importance that evidence-based information could be given to  
426 national and international donor organisations involved with future prevention, control  
427 and research programmes on brucellosis.

428

#### 429 **Acknowledgments**

430 We thank the patients for their willingness to participate in this study. This work was  
431 supported by the Belgian Cooperation in the framework of the Institutional  
432 Collaboration between the Institute of Tropical Medicine in Antwerpen, Belgium and  
433 the International Centre for Zoonoses (CIZ) of Central University of Ecuador.

434

#### 435 **Conflicts of interest**

436 The authors declare that there are no competing financial interests.

437

438 **References**

439

440 Abdoel, TH, Smits, HL. Rapid latex agglutination test for the serodiagnosis of human  
441 brucellosis. *Diagn. Microbiol. Infect. Dis.* 2007; 57:123-128.

442

443 Agasthya, AS, Isloor, S, Prabhudas, K. Brucellosis in high risk group individuals.  
444 *Indian J Med Microbiol* 2007; 25: 28-31.

445

446 Alton, GG, Jones, LM, Angus, RD, Verger, JM. Techniques for the Brucellosis  
447 Laboratory. 1<sup>st</sup> edn. Insitut National de la Recherche Agronomique, Paris (France).  
448 1988.

449

450 Alvarez, P. Situación de la brucelosis en América: panorama general. In: Diagnóstico de  
451 brucelosis animal. Díaz, E, Hernánde, L, Valero, G, Arellano, B. editors. México. 2001;  
452 pp. 9-16.

453

454 Angulo, A, Tufiño, A. Determinación de la Inmunoprevalencia de *Brucella* spp. en  
455 explotaciones ganaderas de los cantones Santo Domingo y El Carmen. [Thesis]. Quito:  
456 Facultad de Medicina Veterinaria y Zootecnia, Universidad Central del Ecuador. 2005.

457 Barroso-García, P, Lucerna, M, Cortés, M, Toranzo, M, et al. Brote de brucelosis  
458 interprovincial por ingesta de queso fresco sin higienizar. *Medicina de Familia (And)*.  
459 2007; 2: 27-32.

460

461 Aznar, MN, Samartino, LE, Humblet, M-F, Saegerman C. Bovine brucellosis in  
462 Argentina and bordering countries: update. *Transboundary Emerging Diseases* 2012, in  
463 press. doi:10.1111/tbed.12018

464

465 Bowden, R. Género *Brucella*. In: Temas de microbiología veterinaria. Stanchi, N,  
466 Martino, P, Gentilini, E, Reinoso, E, Pennimpede, E. Ediciones Sur. Primera edición,  
467 Buenos Aires-Argentina. 1996.

468

469 Bricker, BJ, Halling, SM. Differentiation of *Brucella abortus* bv. 1, 2, and 4, *Brucella*  
470 *melitensis*, *Brucella ovis*, and *Brucella suis* bv. 1 by PCR. J Clin Microbiol 1994;  
471 32:2660-2666.

472

473 Carpenter, CM, Boak, R. *Brucella abortus* in milk and dairy products. Am J Public  
474 Health; 1928; **18**:743-751.

475

476 Casao, MA, Navarro, E, Solera, J. Evaluation of Brucellacapt for the diagnosis of  
477 human brucellosis. J. Infect. 2004; **49**: 102-108.

478

479 Cetin, ES, Kaya, S, Demirci, M, Aridogan, BC. Comparison of the BACTEC blood  
480 culture system versus conventional methods for culture of normally sterile body fluids.  
481 Adv. Ther. 2007; 24(6):1271-1277.

482

483 Cooper, CW. Risk factors in transmission of brucellosis from animals to humans in  
484 Saudi Arabia. Trans R Soc Trop Med Hyg 1992; 86:206-209.

485

486 Dean, AS, Crump, L, Greter, H, Schelling, E, Zinsstag, J. Global burden of human  
487 brucellosis: a systematic review of disease frequency. PLoS Negl. Trop. Dis. 2012 ;  
488 6(10):e1865.

489

490 Delgado, P. Diagnóstico de brucelosis en trabajadores de centros de procesamiento de  
491 cárnicos de Cuenca, mediante seroaglutinación rápida en placa. Doctoral Thesis.  
492 Facultad de Ciencias Agropecuarias, Universidad de Cuenca. 1992; pp. 61.

493

494 Díaz, R, Leiva, J, Rubio, M, Dorronsoro, I. Diagnóstico de la brucelosis humana. In:  
495 Diagnóstico de brucelosis animal. Díaz, E, Hernández, L., Valero, G, Arellano, B.  
496 INIFAP, México, 2001; pp. 198-212.

497

498 Doganay, M, Aygen, B. Human brucellosis: an overview. *Int J Infect Dis.* 2003; 7: 173-  
499 182.

500

501 Dohoo, IR, Martin, W, Stryhn, H. *Veterinary Epidemiologic Research.* AVC Inc:  
502 Charlottetown, Prince Edward Island, Canada. 2003

503

504 [EPI-2] Casos de brucelosis humana reportados en Ecuador (1990-2007).  
505 Epidemiología. Reporte del Ministerio de Salud Pública del Ecuador (EPI-2). 2008

506

507 [FAO and OMS] Comité Mixte FAO/OMS d'experts de la brucellose. Sixieme Rapport.  
508 Organisation Mondial de la Santé, Genève (Suisse), 1986.

509

510 [FAO] Guidelines for Coordinated Human and Animal Brucellosis Surveillance,  
511 Empres emergency prevention system, Rome, 2003.

512

513 Franco, MP, Mulder, M, Gilman, RH, Smits, HL. Human brucellosis. Lancet Infect.  
514 Dis. 2007; 7(12):775-786.  
515

516 Frankena, K, Somers, JG, Schouten, WG, van Stek, JV, et al. The effect of digital  
517 lesions and floor type on locomotion score in Dutch dairy cows. Prev Vet Med. 2009;  
518 88(2):150-7.  
519

520 Grilló, MJ, Barberán, M, Blasco, JM. Transmission of *Brucella melitensis* from sheep to  
521 lambs. Vet. Rec. 1997; 140:602-605.  
522

523 Godfroid, J, Boelaert, F. Prescriptions pour le diagnostic sérologique de la brucellose.  
524 CODA-CERVA (Ed.), Belgium, 1995; pp. 47.  
525

526 Godfroid, J, Nielsen, K, Saegerman, C. Diagnosis of brucellosis in livestock and  
527 wildlife. Croat. Med. J. 2010; 51:296-305.  
528

529 Gómez, MC, Nieto, JA, Rosa, C, Geijo, P, Escribano, MA, Muñoz, A, López, C.  
530 Evaluation of seven tests for diagnosis of human brucellosis in an area where the  
531 disease is endemic. Clin. Vaccine Immunol. 2008; 15(6):1031-1033.  
532

533 Guevara, F, Fuentes J, Barrios, M. Brucelosis en niños, una causa de síndrome febril  
534 prolongado de difícil diagnóstico; revisión a partir de la presentación de un caso.  
535 Revista Colombiana de pediatría, Hospital Universitario Pediátrico de la Misericordia.  
536 Bogotá, Colombia. 2009.  
537 <http://www.encolombia.com/medicina/pediatria/pediatria35400brucelosis.htm>

538

539 Guillén A. *Brucella melitensis* en el hombre: clínica, tratamiento y bioseguridad. In:  
540 Temas de zoonosis III. Cocchione, R, Durlach, R, Larghi, O, Martino, P. Asociación  
541 Argentina de zoonosis, Buenos Aires-Argentina, 2006.

542

543 Hamdy, ME, Amin, AS. Detection of *Brucella* species in the milk of infected cattle,  
544 sheep, goats and camels by PCR. Vet J. 2002; 163:299-305.

545

546 Hernández, A, García, P, Cruz, A, Rojo, J. Seroprevalencia de brucelosis en  
547 disponentes de sangre del Hospital General de México. Revista Médica del Hospital  
548 General de México S.S. Vol. 62, México, 1999; pp. 107-112.

549

550 [INEC] Anuario de estadísticas hospitalarias. In: Informe Analítico, Quito-Ecuador,  
551 2008; pp. 82, 92, 64.

552

553 Intriago, W. Investigación de brucelosis en porcinos sacrificados en el matadero de la  
554 ciudad de Portoviejo, mediante la prueba de sero-aglutinación en placa. Doctoral Thesis.  
555 Facultad de Ciencias Veterinarias. Universidad Técnica de Manabí, 1971; pp.151.

556

557 Issa, H, Jamal, M. Brucellosis in children in south Jordan. East Mediterr. Health J.  
558 1999; 5:895-902.

559

560 Kalaajieh, WK. Epidemiology of human brucellosis in Lebanon in 1997. Med Mal  
561 Infect. 2000; 30: 43-46.

562

563 Lucero, NE, Ayala, SM, Escobar, GI, Jacob, NR. *Brucella* isolated in humans and  
564 animals in Latin America from 1968 to 2006. *Epidemiol and Infect.* 2008; 136:496-503.  
565  
566 [MAG-SESA] Prevención y control de la brucelosis bovina en Ecuador. Ministerio de  
567 Agricultura y Ganadería, Servicio Ecuatoriano de Sanidad Agropecuaria, 1999.  
568  
569 Mantur, BG, Biradar, MS, Bidri, RC, Mulimani, MS, Veerappa, Kariholu P, Patil SB,  
570 Mangalgi SS. Protean clinical manifestations and diagnostic challenges of human  
571 brucellosis in adults: 16 years' experience in an endemic area. *J Med Microbiol.* 2006;  
572 55:897-03  
573  
574 Mantur, BG, Amarnath, SK, Shinde, RS. Review of clinical and laboratory features of  
575 human brucellosis. *Indian J Med Microbiol.* 2007; 25(3):188-02.  
576  
577 Mekey, FA, Hassan, EA, Elhafez, A, Aboul, FAM, El-Ghazali, S.M. Epidemiology and  
578 risk factors of brucellosis in Alexandria governorate. *East Mediterr Health J.*  
579 2007;13(3):677-85  
580  
581 McDevitt, DG. Brucellosis and the veterinary surgeon. *Vet Rec.* 1971; 21: 537-9  
582  
583 Minas, M, Minas, A, Gourgulianis, K, Stournara, A. Epidemiological and clinical  
584 aspects of human brucellosis in Central Greece. *Jpn. J. Infect. Dis.* 2007; 60: 362-366.  
585



586 Moriyón, I, Díaz, R, López-Goñi, I. Bacteriología del género *Brucella*. In: Manual de  
587 brucelosis. Rodríguez, T, Orduña, A, Ariza, X, Morrión, I, Díaz, Ret al. Junta de  
588 Castilla y León. España. 2001; pp. 21-30.

589

590 Organización Panamericana de la Salud [OPS]. Perfil de Sistema de Salud: Ecuador,  
591 monitoreo y análisis de los procesos de cambio y reforma. Washington, D.C., OPS  
592 (ed.), Third Edition, 2008, pp. 68.

593

594 Omer, MK, Assefaw, T, Skjerve, E, Tekleghiorghis, T, Woldehiwet Z. Prevalence of  
595 antibodies to *Brucella* spp. and risk factors related to high-risk occupational groups in  
596 Eritrea. Epidemiol Infect. 2002; 129:85-91

597

598 Pappas, G, Papadimitriou P., Akritidis N, Christou, L, Tsianos, EV. The new global  
599 map of human brucellosis. Lancet Infect Dis. 2006; 6:91-99.

600

601 Pila-Perez, R, Pila-Peláez, R, Basulto, M, Hernández, O, Peña,PG, Vadella, G. Estudio  
602 clínico de la brucelosis humana. Revista Médica Uruguay, 1997; 13:110-117.

603

604 Rahman, A, Berkvens, D, Fretin, D, Saegerman, C, Ahmed, MU, Muhammad, N,  
605 Hossain, A, Abatih, E. Sero-prevalence and risk factors for brucellosis in high risk  
606 group individuals in Bangladesh. Foodborne Pathog Dis. 2012; 9(3):190-197.

607

608 Ron-Román J, Saegerman C, Minda-Aluisa E, Benítez-Ortíz, W, Brandt, J, Douce, R.  
609 Case report: First report of orchitis in man caused by *Brucella abortus* biovar 1 in

610 Ecuador. *American Journal of Tropical Medicine and Hygiene*. Published online: 23  
611 July 2012. doi: 10.4269/ajtmh.2012.11-0341.

612

613 Roux, J. Epidemiology and prevention of brucellosis. *Bull World Health Organ*. 1979;  
614 57: 179-194.

615

616 Saegerman, C, Berkvens, D, Godfroid, J, Walravens, K. Chapter 77: Bovine brucellosis.  
617 *In: Infectious and Parasitic Disease of Livestock*. Lavoisier et Commonwealth  
618 Agricultural Bureau – International (ed.), France, 2010; pp. 971-1001.

619

620 Serra, J, Godoy, P. Incidencia, etiología y epidemiología de la brucelosis en un área  
621 rural de la provincia de Lleida, *Rev Esp Salud Pública*. 2000; 74:45-53.

622

623 Shehata, A, Salim, MA, Al-Anzi, AA. Risk factors and clinical presentation of  
624 brucellosis in Al-Jahra Hospital (1997-1999). *Kuwait Med. J*. 2001; 33(1):44-7

625

626 Snijders, TAB, Bosker, RJ. *Multilevel analysis: an introduction to basic and advanced*  
627 *multilevel modeling*. SAGE publications Ltd:6 Bonhill Street, London EC2A, 4PU.  
628 1999.

629

630 Soudbakhsh, A, Mortazavi, H, Hajiabdolbaghi, M, Hasibi, M, Jafari, S, Emadi, H,  
631 Esmaili Djavid, JH. Determination of the optimal cut-off point for ELISA test for  
632 diagnosis of brucellosis. *Tehran University Medical Journal* 2009; 67:415-420.

633

634 Thiange, P, Saegerman, C, Botton, Y, Limet, JN. Brucellose bovine : le test  
635 d'agglutination en presence de facteur rhumatoïde après traitement du sérum par le

636 dithiothreitol dans la différenciation des animaux vaccinés et infectés. Annales de  
637 Médecine Vétérinaire 1992 ; 136:471-476.

638

639 Torres, J, López, A, García, R, Gutiérrez, J. Seroprevalencia de anticuerpos anti –  
640 *Brucella* en disponentes de sangre con fines terapéuticos en tres bancos de sangre del  
641 Instituto Mexicano del Seguro Social. Gac. Méd. Mex. 2004; 140:145-148.

642

643 Torres, H. Control de Brucelosis Bovina – Programa Nacional. Ministerio de  
644 Agricultura, Ganadería, Acuacultura y Pesca (MAGAP), Servicio Ecuatoriano de  
645 Saniidad Agropecuaria (SESA). Quito, Ecuador, 2008; pp. 30.

646

647 Twisck, JWR. Applied Longitudinal Data Analysis for Epidemiology: A practical  
648 guide. Cambridge University Press. 2003

649

650 VanLeeuwen, JA, Haddad, JP, Dohoo, IR, Keefe, GP, Tiwari, A, Scott, HM. Risk  
651 factors associated with *Neospora caninum* seropositivity in randomly sampled Canadian  
652 dairy cows and herds. Prev. Vet. Med. 2010; 93(2-3):129-38

653

654 Wassif, SM, El-Samra, AGH, El-Sabbagh, F, Aboel-Seoud, AR. Brucellosis in Shakira  
655 Governorate, an epidemiological study. Egypt. J. Commun. Med. 1992; 10(1):147-158

656

657 [WHO] World Health Organization. Brucellosis in humans and animals.  
658 WHO/CDS/EPR/2006.7. Geneva, Switzerland, 2006; pp. 36-56

659

660 Yagupsky, P. Detection of *Brucella melitensis* by BACTEC NR660 Blood Culture  
661 System. J. Clin. Microbiol. 1994; 32(8):1899-1901.

662

663 Young, E. Especies de *brucella*. In: Enfermedades infecciosas principios y prácticas.

664 Cuarta Edición. Mandell, G, Bennett, J, Dolin, R, editors. Editorial Médica

665 Panamericana, Buenos Aires, 1997; pp. 2301-230

666

667

668


669

670

671

672

Figure 1: Location of the study area



673


674

675

676

677 **Figure 2.** PCR – AMOS of *Brucella* from blood cultures, isolated from positive  
678 persons.

679



680

681

682 Legend: MP: Molecular weight marker, B2: control *Brucella abortus* biotype 2, H1: Human sample 1  
683 (Ec-CIZ-Hum-1), H2: Human sample 2 (Ec-CIZ-Hum-2); \*: Samples from complementary studies at  
684 CIZ; CB: Blank control.

685

686

687 **Table I.** Human brucellosis in North-West Ecuador: results of three diagnostic assays  
 688

RB	SAT-EDTA	iELISA	SLA	OTH	Number (%)
-	-	-	516	3,147	3,663 (98.12)
-	-	+	2	5	7 (0.19)
-	+	-	0	0	0 (0)
-	+	+	1	1	2 (0.05)
+	-	-	1	10	11 (0.29)
+	-	+	17	14	31 (0.83)
+	+	-	1	0	1 (0.03)
+	+	+	4	14	18 (0.48)
Total			542	3,191	3,733 (100)

689  
 690 Legend: RB: Rose Bengal; SAT-EDTA: Wright's Slow Agglutination Test with EDTA;  
 691 iELISA: Enzyme Linked Immunosorbent Assay; SLA: people working in a  
 692 slaughterhouse; OTH: other people.

693  
 694

695 **Table II.** Detailed information from six seropositive patients under 18 years old

696

N°	Province	Canton	Age	Sex	Membership	Contact with livestock	Contact with foetal secretions	Consumption of milk	Consumption of placenta and foetus	Consumption of blood	RB	SAT-EDTA (UI/ml)	iELISA (U/ml)
1	Pichincha	Mejía	10	M	farm	+	-	boiled	-	-	-	50	30
2	Pichincha	Mejía	16	F	farm	+	+	raw	-	-	-	30	30
3	Pichincha	Mejía	17	M	farm	+	-	boiled	-	-	+	80	60
4	Imbabura	Ibarra	11	F	rural community	-	-	raw	-	-	+	-	-
5	Imbabura	Ibarra	10	M	rural community	-	-	boiled	-	-	+	30	-
6	Imbabura	Urququí	17	F	rural community	+	+	boiled	-	-	+	30	-

697

698

699 Legend: RB: Rose Bengal; SAT-EDTA: Wright's Slow Agglutination Test; iELISA: indirect Enzyme Linked Immunosorbent Assay.



700 **Table III.** Distribution of seropositive results and potential risk factors for human  
 701 brucellosis in the north western part of Ecuador

<b>Factor</b>	<b>Tested</b>	<b>Seropositives (%)</b>	<b>Odds ratio</b>	<b>95% C. I.</b>	<b>p-value</b>
<b>Age (years)</b>					
<=15	681	3 (0.4)	1	ref	0.0252
From 16 to 45	2382	50 (2.1)	4.4	1.3-14.6	
>=46	667	17 (2.5)	4.5	1.3-16.0	
<b>Sex</b>					
Women	1570	22 (1.4)	1	ref	0.0415
Men	2163	48 (2.2)	1.7	1.0-2.9	
<b>Region</b>					
Tropics	1185	16 (1.4)	1	ref	0.1013
Sierra	2548	54 (2.1)	1.580.7	0.89-3.00	
<b>Occupational hazard group*</b>					
Low	3191	44 (1.4)	1	ref	0.0027
High	542	26 (4.8)	2.5	1.4-4.4	
<b>Contact with livestock</b>					
No	724	7 (1.0)	1	ref	0.0006
Yes	3009	63 (2.1)	3.7	1.6-8.6	
<b>Contact with foetal secretions</b>					
No	2159	27 (1.3)	1	ref	0.0169
Yes	1574	43 (2.7)	1.9	1.1-3.1	
<b>Consumption of raw milk</b>					
No	2848	49(1.7)	1	ref	0.1886
Yes	885	21(2.4)	1.5	0.8-2.5	
<b>Consumption of cheese</b>					
No	280	8 (2.9)	1	ref	0.8277
Yes	3453	62 (1.8)	1.1	0.5-2.4	
<b>Consumption of placenta and foetus</b>					
No	3528	60(1.7)	1	ref	0.0169
Yes	205	10(4.9)	2.7	1.3-5.5	
<b>Consumption of blood</b>					
No	3424	58(1.7)	1	ref	0.0515
Yes	309	12(3.9)	2.0	1.0-4.0	
<b>Province**</b>					
Carchi	649	16 (2.5)			
Esmeralda	195	5 (2.6)			
Imbabura	1032	13 (1.3)			
Manabí	377	11 (2.9)			
Pichincha	1480	25 (1.7)			

702

703

704 Legend: ref, stands for reference category; C.I., confidence interval, \*see definition in  
705 materials and methods section; \*\* this variable was used as a random effect in the  
706 logistic regression analysis. The p-values are based on the likelihood ratio test  
707 comparing the random intercepts-only model and the random effects model with each  
708 covariate in turn.  
709

710 **Table IV.** Final model of risk factors associated with human brucellosis sero-positivity  
 711 among people in the north-western part of Ecuador based on a multivariate random  
 712 effects logistic regression analysis  
 713

<b>Risk factors</b>	<b>OR</b>	<b>P- value</b>	<b>95% Confidence Interval</b>
<b>Consumption of fetus and placenta</b>			
No	1	-	ref.
Yes	2.5	0.016	(1.18-5.22)
<b>Contact with livestock</b>			
No	1	-	ref.
Yes	3.0	0.014	(1.25-7.08)
<b>Occupational hazard group</b>			
Low	1	-	ref.
High	1.8	0.049	(1.00-3.35)
<b>Variance components</b>			
	<b>Estimate</b>	<b>S. E.</b>	
Canton	<b>115</b>	<b>081</b>	<b>( 072- 185)</b>
Province	<b>00</b>	<b>029</b>	<b>*</b>

714  
 715 Legend: \*, 95% Confidence interval was not estimated by the model; ref, stands for  
 716 reference category.

717  
 718

719 **Table V.** Results of blood cultures from patients with high serological titres concomitant with brucellosis presumptive clinical symptoms (North-  
720 West Ecuador)

Nº	Province	Age (year)	Sex	Occupation	Contact with livestock	Contact with foetal secretions	Consumption of milk	Consumption of placenta and foetus	Consumption of blood	RB	SAT-EDTA (UI/ml)	iELISA (U/ml)	Blood culture
1	Pichincha	28	M	Farmer	+	+	boiled	-	-	+	-	60	-
2	Pichincha	22	M	Farmer	+	+	boiled	-	-	+	100	60	-
3	Pichincha	17	M	Student	+	-	boiled	-	-	+	80	60	-
4	Pichincha	49	F	Farmer	+	+	raw	-	-	-	80	-	-
5	Pichincha	28	M	Farmer	+	+	boiled	-	-	-	-	30	-
6	Pichincha	49	F	Farmer	+	-	raw	-	-	+	100	60	-
7	Pichincha	50	M	Farmer	+	+	boiled	-	-	-	50	-	-
8	Pichincha	39	M	Farmer	+	+	boiled	+	-	+	100	60	-
9	Pichincha	41	M	Veterinary lecturer	+	+	boiled	-	-	+	80	60	-
10	Pichincha	26	M	Farmer	+	+	raw	+	-	+	100	60	-
11	Pichincha	39	M	Farmer	+	+	boiled	-	-	+	100	60	-
12	Pichincha	41	M	Farmer	+	+	boiled	+	+	-	100	60	-
13	Pichincha	39	F	Slaughterhouse worker	+	+	boiled	-	-	+	50	60	-
14	Carchi	42	M	Slaughterhouse worker	+	+	boiled	-	-	+	40	60	-
15	Carchi	55	M	Transporter	+	-	raw	-	-	+	-	50	-
16	Carchi	50	F	Slaughterhouse worker	+	+	raw	-	-	+	-	48.6	-
17	Carchi	66	F	Slaughterhouse worker	+	+	raw	+	+	+	60	60	-
18	Carchi	36	F	Slaughterhouse worker	+	+	boiled	-	-	+	320	14.4	+
19	Carchi	35	M	Slaughterhouse worker	+	+	boiled	-	-	+	100	26.2	-
20	Pichincha	27	M	Veterinary student	+	-	boiled	-	-	+	1600	60	+
21	Carchi	58	M	Farmer	+	-	raw	-	+	+	800	60	+
22	Carchi	21	M	Farmer	+	+	raw	-	-	+	960	60	-

721

722

723 Legend: RB: Rose Bengal; SAT-EDTA: Wright's Slow Agglutination Test; iELISA: indirect Enzyme Linked Immunosorbent Assay.

724 **Table VI.** *In vitro* characteristics of the isolations (group with people under high risk)

725

726

Sample code serology	Sample code bacteriology*	Urease activity	CO <sub>2</sub> for growth	H <sub>2</sub> S production	Growth on colorants				Agglutination with serum	
					Thionine 20 µg	Thionine 10 µg	Basic fuchsin 20 µg	Safranin 100 µg	A	M
SHB-Cam-Nor-152	Ec-CIZ-Hum1	+	+	+	-	-	+	+	-	+
SHB-Ay-10	Ec-CIZ-Hum2	+	+	+	-	-	-	-	-	+
SHB-Zon-Nor-370	Ec-CIZ-Hum3	+	+	+	+	-	+	+	-	+

727

728

729

730 Legend: \*= blood culture.

731 **Table VII.** Human brucellosis: symptoms and frequency (N = 70 inhabitants sero-  
732 positive to at least one of the three diagnostic tests for brucellosis)  
733

<b>Symptoms</b>	<b>Positive cases</b>	<b>%</b>
Muscular pain	29	41.43
Joint pain	25	35.71
Fever	17	24.29
Debility	17	24.29
Headache	16	22.86
Nocturnal sweating	13	18.57
Cardiac problems	10	14.29
Anorexia	4	5.71
Insomnia	4	5.71
No apparent symptoms	17	24.29

734

735

736